Key Takeaways
- • OpZira™, Inc., an ophthalmic medical device company focused on detection and monitoring of ocular disease, has been selected to present at the 2026 New York Venture Summit.
- • The summit takes place November 18-19, 2026, at the Javits Center in New York City, and is hosted by youngStartup Ventures.
- • Approximately 200 companies were selected to present to an audience that includes venture capital firms and corporate investors.
- • The announcement was issued via Business Wire and positions OpZira's ophthalmic device technologies for investor exposure.
Summary
OpZira™, Inc., a Middletown, Pennsylvania-based ophthalmic medical device company, announced that it has been selected to present its technologies at the 2026 New York Venture Summit, according to a Business Wire press release. The company develops technologies for the detection and monitoring of ocular disease.
The summit is scheduled for November 18-19, 2026, at the Javits Center in New York City. It is hosted by youngStartup Ventures and will feature 200 innovative companies selected to present their technologies and growth opportunities. The audience is described as including venture capital firms and corporate participants.
The release is a company-issued announcement of event selection. It does not disclose financial terms, funding targets, valuation, or specific product milestones, and the available source text is truncated, so further details on OpZira's technology pipeline or commercial status could not be verified from the material reviewed.
The summit is scheduled for November 18-19, 2026, at the Javits Center in New York City. It is hosted by youngStartup Ventures and will feature 200 innovative companies selected to present their technologies and growth opportunities. The audience is described as including venture capital firms and corporate participants.
The release is a company-issued announcement of event selection. It does not disclose financial terms, funding targets, valuation, or specific product milestones, and the available source text is truncated, so further details on OpZira's technology pipeline or commercial status could not be verified from the material reviewed.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.